Lilly/Daiichi Submit Prasugrel; Showdown With Plavix Timed For Second Half

Lilly and Daiichi Sankyo plan to launch the antiplatelet drug prasugrel immediately after it is approved, supported by an extensive sales force including representatives from both companies